D. E. Shaw & Co. Inc. Buys 68,474 Shares of Cryoport, Inc. (NASDAQ:CYRX)

D. E. Shaw & Co. Inc. raised its holdings in Cryoport, Inc. (NASDAQ:CYRX - Free Report) by 20.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 408,385 shares of the company's stock after acquiring an additional 68,474 shares during the period. D. E. Shaw & Co. Inc. owned about 0.83% of Cryoport worth $3,177,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. SG Americas Securities LLC grew its holdings in shares of Cryoport by 44.8% in the 4th quarter. SG Americas Securities LLC now owns 146,789 shares of the company's stock valued at $1,142,000 after acquiring an additional 45,430 shares in the last quarter. Rhumbline Advisers increased its holdings in Cryoport by 2.9% in the 4th quarter. Rhumbline Advisers now owns 63,284 shares of the company's stock valued at $492,000 after buying an additional 1,764 shares during the period. JPMorgan Chase & Co. grew its position in Cryoport by 1,464.4% in the third quarter. JPMorgan Chase & Co. now owns 305,237 shares of the company's stock valued at $2,475,000 after acquiring an additional 285,726 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in Cryoport by 8.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 60,003 shares of the company's stock worth $467,000 after acquiring an additional 4,902 shares during the last quarter. Finally, Thrivent Financial for Lutherans bought a new position in shares of Cryoport during the fourth quarter valued at $299,000. 92.90% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Cryoport

In related news, CEO Jerrell Shelton sold 4,620 shares of Cryoport stock in a transaction on Monday, March 17th. The stock was sold at an average price of $6.29, for a total transaction of $29,059.80. Following the sale, the chief executive officer now directly owns 765,399 shares in the company, valued at approximately $4,814,359.71. This trade represents a 0.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold a total of 19,830 shares of company stock valued at $118,353 over the last ninety days. 10.00% of the stock is currently owned by insiders.

Cryoport Stock Down 2.9%

Shares of NASDAQ CYRX traded down $0.18 during midday trading on Friday, hitting $6.04. 253,099 shares of the stock traded hands, compared to its average volume of 544,154. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. Cryoport, Inc. has a one year low of $4.58 and a one year high of $11.64. The business has a 50 day moving average price of $5.93 and a two-hundred day moving average price of $6.82. The company has a market cap of $302.83 million, a PE ratio of -1.79 and a beta of 1.92.

Cryoport (NASDAQ:CYRX - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01. The firm had revenue of $41.04 million for the quarter, compared to analyst estimates of $56.19 million. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. On average, equities analysts predict that Cryoport, Inc. will post -0.99 EPS for the current year.

Analyst Ratings Changes

A number of research firms have recently commented on CYRX. Needham & Company LLC reaffirmed a "buy" rating and issued a $11.00 price objective on shares of Cryoport in a research note on Thursday, May 8th. Guggenheim reaffirmed a "buy" rating and set a $10.00 price target on shares of Cryoport in a research report on Wednesday, April 16th. UBS Group increased their price target on Cryoport from $10.00 to $11.00 and gave the stock a "buy" rating in a report on Tuesday, April 1st. Roth Mkm reissued a "buy" rating and issued a $15.00 price objective on shares of Cryoport in a research note on Tuesday, April 1st. Finally, Morgan Stanley decreased their target price on Cryoport from $8.00 to $7.00 and set an "equal weight" rating for the company in a research note on Monday, May 5th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $11.00.

Cryoport Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.